Jump to content

User:Reph-415

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Reph-415 (talk | contribs) at 12:36, 7 August 2023. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

HOW
Names
Other names
WHY
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Hi
I have tons of sexual intercourse all the time.[citation needed]

to do

  • Iboga alkaloid - Probably should be renamed to either "iboga-type alkaloid" or "substituted ibogamines". I submitted an attempt at making the article more detailed, and more sourced. I also (kind of) removed a weird attempt at promoting synthetic abominations that have little to do with iboga itself (18-MC).
  • Iboluteine (ibogaine pseudoindoxyl) - An ibogaine oxydation product, analogous to the poorly studied opioid mitragynine pseudoindoxyl. Iboluteine and related metabolites possibly contribute to iboga's therapeutic effects. UPDATE : Unfortunately, research about iboga and its alkaloids has come to a crawling stop because of insane anti-drug propaganda from france and north america.

List of non-hallucinogenic 5-HT2A agonists

Tryptamines

Mescaline analogs

Others

List of atypical monoamine transporter ligands

There are many similar and/or contradicting hypotheses about monoamine transporter binding sites, here are some of them.

SERT

4-TFMMC, an SERT negative allosteric modulator
Compound 7a, an SERT positive allosteric modulator

NET

  • Nothing ? NET is not an interesting target apparently.

DAT

  • Difluoropine, "inward-facing" reuptake inhibitor
  • Vanoxerine, "inward-facing" reuptake inhibitor
  • Modafinil, "inward-facing" reuptake inhibitor
  • SoRI-20041, "antagonist-like" reuptake inhibitor that counterintuitively doesn't antagonize amphetamine-mediated (transporter-mediated) dopamine release.

Others